These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 22006329)
1. Antitumorigenic potential of STAT3 alternative splicing modulation. Zammarchi F; de Stanchina E; Bournazou E; Supakorndej T; Martires K; Riedel E; Corben AD; Bromberg JF; Cartegni L Proc Natl Acad Sci U S A; 2011 Oct; 108(43):17779-84. PubMed ID: 22006329 [TBL] [Abstract][Full Text] [Related]
2. Oligonucleotide-directed STAT3 alternative splicing switch drives anti-tumorigenic outcomes in MCF10 human breast cancer cells. Tano V; Jans DA; Bogoyevitch MA Biochem Biophys Res Commun; 2019 Jun; 513(4):1076-1082. PubMed ID: 31010684 [TBL] [Abstract][Full Text] [Related]
3. PCBP1 inhibits the expression of oncogenic STAT3 isoform by targeting alternative splicing of STAT3 exon 23. Wang X; Guo J; Che X; Jia R Int J Biol Sci; 2019; 15(6):1177-1186. PubMed ID: 31223278 [TBL] [Abstract][Full Text] [Related]
4. STAT3beta, a distinct isoform from STAT3. Zhang HX; Yang PL; Li EM; Xu LY Int J Biochem Cell Biol; 2019 May; 110():130-139. PubMed ID: 30822557 [TBL] [Abstract][Full Text] [Related]
5. Selective STAT3-α or -β expression reveals spliceform-specific phosphorylation kinetics, nuclear retention and distinct gene expression outcomes. Ng IH; Ng DC; Jans DA; Bogoyevitch MA Biochem J; 2012 Oct; 447(1):125-36. PubMed ID: 22799634 [TBL] [Abstract][Full Text] [Related]
6. Alternative Splicing of STAT3 Is Affected by RNA Editing. Goldberg L; Abutbul-Amitai M; Paret G; Nevo-Caspi Y DNA Cell Biol; 2017 May; 36(5):367-376. PubMed ID: 28278381 [TBL] [Abstract][Full Text] [Related]
7. Stat3 isoforms, alpha and beta, demonstrate distinct intracellular dynamics with prolonged nuclear retention of Stat3beta mapping to its unique C-terminal end. Huang Y; Qiu J; Dong S; Redell MS; Poli V; Mancini MA; Tweardy DJ J Biol Chem; 2007 Nov; 282(48):34958-67. PubMed ID: 17855361 [TBL] [Abstract][Full Text] [Related]
8. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells. Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192 [TBL] [Abstract][Full Text] [Related]
9. The Opposing Function of STAT3 as an Oncoprotein and Tumor Suppressor Is Dictated by the Expression Status of STAT3β in Esophageal Squamous Cell Carcinoma. Zhang HF; Chen Y; Wu C; Wu ZY; Tweardy DJ; Alshareef A; Liao LD; Xue YJ; Wu JY; Chen B; Xu XE; Gopal K; Gupta N; Li EM; Xu LY; Lai R Clin Cancer Res; 2016 Feb; 22(3):691-703. PubMed ID: 26405196 [TBL] [Abstract][Full Text] [Related]
10. Identification of two Stat3 variants lacking a transactivation domain in grass carp: New insights into alternative splicing in the modification of teleost Stat3 signaling. Wang X; Du L; Wei H; Zhang A; Yang K; Zhou H Fish Shellfish Immunol; 2018 Jun; 77():13-21. PubMed ID: 29555584 [TBL] [Abstract][Full Text] [Related]
11. Of alphas and betas: distinct and overlapping functions of STAT3 isoforms. Dewilde S; Vercelli A; Chiarle R; Poli V Front Biosci; 2008 May; 13():6501-14. PubMed ID: 18508676 [TBL] [Abstract][Full Text] [Related]
12. STAT3 isoforms: Alternative fates in cancer? Aigner P; Just V; Stoiber D Cytokine; 2019 Jun; 118():27-34. PubMed ID: 30031681 [TBL] [Abstract][Full Text] [Related]
13. STAT3β is a tumor suppressor in acute myeloid leukemia. Aigner P; Mizutani T; Horvath J; Eder T; Heber S; Lind K; Just V; Moll HP; Yeroslaviz A; Fischer MJM; Kenner L; Győrffy B; Sill H; Grebien F; Moriggl R; Casanova E; Stoiber D Blood Adv; 2019 Jul; 3(13):1989-2002. PubMed ID: 31270081 [TBL] [Abstract][Full Text] [Related]
14. Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo. Emmrich S; Wang W; John K; Li W; Pützer BM Mol Cancer; 2009 Aug; 8():61. PubMed ID: 19671150 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice. Zhang X; Zhang J; Wang L; Wei H; Tian Z BMC Cancer; 2007 Aug; 7():149. PubMed ID: 17683579 [TBL] [Abstract][Full Text] [Related]
17. Small-molecule targeting of signal transducer and activator of transcription (STAT) 3 to treat non-small cell lung cancer. Lewis KM; Bharadwaj U; Eckols TK; Kolosov M; Kasembeli MM; Fridley C; Siller R; Tweardy DJ Lung Cancer; 2015 Nov; 90(2):182-90. PubMed ID: 26410177 [TBL] [Abstract][Full Text] [Related]
18. Specific ablation of Stat3beta distorts the pattern of Stat3-responsive gene expression and impairs recovery from endotoxic shock. Yoo JY; Huso DL; Nathans D; Desiderio S Cell; 2002 Feb; 108(3):331-44. PubMed ID: 11853668 [TBL] [Abstract][Full Text] [Related]
19. A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signaling. Hu G; Witzig TE; Gupta M PLoS One; 2013; 8(7):e67851. PubMed ID: 23861822 [TBL] [Abstract][Full Text] [Related]
20. STAT3beta does not interfere with granulocyte colony-stimulating factor-induced neutrophilic differentiation. de Koning JP; Ward AC; Caldenhoven E; de Groot RP; Löwenberg B; Touw IP Hematol J; 2000; 1(4):220-5. PubMed ID: 11920194 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]